Drug Trial News

RSS

Gilead presents Phase IIa data for HCV therapy at The Liver Meeting 2010

Gilead Sciences, Inc. today announced data from a Phase IIa study showing that its investigational compounds GS 9190 and GS 9256, used in conjunction with current standard of care therapies, produced substantial suppression of the hepatitis C virus (HCV) within 28 days of treatment.

1 Nov 2010

Anadys presents data of ANA598 for hepatitis C treatment at AASLD Annual Meeting

Anadys Pharmaceuticals, Inc. today announced the ANA598 data to be presented at the 61st Annual Meeting of the American Association for the Study of Liver Disease (AASLD) in Boston, MA.

1 Nov 2010

OptiNose presents sumatriptan Phase II trial results at 2nd European Headache and Migraine Trust International

OptiNose Inc. announced the results from an analysis comparing the Phase II clinical trial obtained with its novel delivery technology to that of other formulations. The analysis suggests rapid absorption rate alone may not explain the efficacy in migraines treated with sumatriptan delivered with the Company's novel bi-directional technology. The results will be presented at the 2nd European Headache and Migraine Trust International on 28th of October 2010.

30 Oct 2010

Presidio to present PPI-461 data for HCV infection at AASLD meeting

Presidio Pharmaceuticals, Inc. announced today that Nathaniel Brown, M.D., Chief Medical Officer, will present a late-breaker poster, "Safety and Pharmacokinetics of PPI-461, a Potent New Hepatitis C virus (HCV) NS5A Inhibitor with Pan-Genotype Activity" at the 61st AASLD meeting in Boston, MA, on November 1, 2010.

30 Oct 2010

CONCERTA improves handwriting performance in children with ADHD: Study

Data presented today at a major medical meeting include findings that demonstrate improved handwriting performance in children with Attention Deficit Hyperactivity Disorder (ADHD) when taking CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) compared to placebo.

30 Oct 2010

Cipher announces completion of patient enrolment in CIP-ISOTRETINOIN Phase III study for nodular acne

30 Oct 2010

Alnylam to present data on RNAi therapeutics for fibrotic diseases at The Liver Meeting

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today it will present several poster presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases being held in Boston, Mass from October 29 - November 2, 2010.

30 Oct 2010

Idera presents data on TLR 3 agonist as vaccine adjuvants at Immunological Meeting

Idera Pharmaceuticals, Inc. today announced a presentation describing the chemistry and immunological activity of its proprietary Toll-Like Receptor (TLR) 3 agonist compounds and the use of these compounds as vaccine adjuvants in a preclinical model.

30 Oct 2010

AVEO to raise $61 million through private placement

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the execution of a securities purchase agreement with a select group of institutional and accredited investors providing for a private placement, or PIPE financing.

30 Oct 2010

OHSU to lead next phase of HuCNS-SC trial for NCL in children

Oregon Health & Science University Doernbecher Children's Hospital will lead the next phase of a landmark clinical trial to further assess the safety and preliminary effectiveness of purified human neural stem cells (HuCNS-SC-) as a potential treatment for infantile or late-infantile neuronal ceroid lipofuscinosis (NCL), a rare and currently fatal neurodegenerative disorder that affects infants and children.

30 Oct 2010

Cipher completes enrolment in CIP-ISOTRETINOIN Phase III study for severe, nodular acne

Cipher Pharmaceuticals Inc. today announced that it has completed patient enrolment in its Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of isotretinoin, which is used in the treatment of severe, nodular acne. The Phase III safety study is being conducted under a Special Protocol Assessment that was granted by the U.S. Food and Drug Administration (FDA).

29 Oct 2010

MAP Pharmaceuticals to present FREEDOM-301 Phase 3 trial data for migraine at EHMTIC Congress

MAP Pharmaceuticals, Inc. today announced new data from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX orally inhaled migraine therapy showing low recurrence rates with LEVADEX. Eight additional analyses from the LEVADEX program also will be presented during the 2010 European Headache and Migraine Trust International Congress (EHMTIC) in Nice, France.

29 Oct 2010

GSK and Amicus announce Amigal development and commercialization agreement

GlaxoSmithKline PLC (GSK) and Amicus Therapeutics today announced a definitive agreement to develop and commercialize Amigal™ (migalastat HCl), currently in Phase 3 for the treatment of Fabry disease, a rare inherited disorder. Under the terms of the agreement, GSK will receive an exclusive worldwide license to develop, manufacture and commercialize migalastat HCl.

29 Oct 2010

Shire announces results of Vyvanse Phase 2 signal finding study for Major Depressive Disorder

Shire plc the global specialty biopharmaceutical company, today announced results from a Phase 2 signal finding study of Vyvanse(R) [lisdexamfetamine dimesylate (or SPD489)] in patients who have had residual symptoms of depression following treatment with LEXAPRO(escitlopram) for Major Depressive Disorder (MDD).

29 Oct 2010

57% of ALK-positive advanced non-small cell lung cancer patients respond to crizotinib: Study

A study in the New England Journal of Medicine shows more than half of patients with a specific kind of lung cancer are responding positively to a treatment that targets the gene that drives their cancer.

29 Oct 2010

ImmuneRegen's Homspera enhances survival of animals vaccinated with experimental melanoma vaccine

ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR BioSciences Holdings, Inc., today announced that treatment with its lead compound, Homspera®, improved the survival of animals vaccinated with an experimental melanoma vaccine.

29 Oct 2010

Coadministration of INTUNIV tablets with stimulant reduces ADHD symptoms

Shire plc the global specialty biopharmaceutical company, today presented research results of once-daily INTUNIV (guanfacine) Extended-Release Tablets, coadministered with stimulants in children and adolescents diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) who had suboptimal response to treatment with a long-acting stimulant alone.

29 Oct 2010

Forest, Almirall report topline results from aclidinium bromide comparative Phase III study in COPD

Forest Laboratories, Inc. and Almirall, S.A. today announced top-line results from ACCORD COPD II, a 12-week Phase III study comparing the efficacy and safety of inhaled aclidinium bromide, an investigative bronchodilator, to placebo in 544 patients with moderate to severe COPD.

29 Oct 2010

StemCells initiates HuCNS-SC second clinical trial for Batten disease in children

StemCells, Inc. announced today that it has initiated a second clinical trial of its HuCNS-SC product candidate (purified human neural stem cells) in neuronal ceroid lipofuscinosis (NCL, also often referred to as Batten disease), a fatal neurodegenerative disorder in children.

29 Oct 2010

Geron 2010 third quarter revenue increases from $494,000 to $546,000

Geron Corporation today reported financial results for the three and nine months ended September 30, 2010.

29 Oct 2010

Drug Trial News

Gilead presents Phase IIa data for HCV therapy at The Liver Meeting 2010

Anadys presents data of ANA598 for hepatitis C treatment at AASLD Annual Meeting

OptiNose presents sumatriptan Phase II trial results at 2nd European Headache and Migraine Trust International

Presidio to present PPI-461 data for HCV infection at AASLD meeting

CONCERTA improves handwriting performance in children with ADHD: Study

Cipher announces completion of patient enrolment in CIP-ISOTRETINOIN Phase III study for nodular acne

Alnylam to present data on RNAi therapeutics for fibrotic diseases at The Liver Meeting

Idera presents data on TLR 3 agonist as vaccine adjuvants at Immunological Meeting

AVEO to raise $61 million through private placement

OHSU to lead next phase of HuCNS-SC trial for NCL in children

Cipher completes enrolment in CIP-ISOTRETINOIN Phase III study for severe, nodular acne

MAP Pharmaceuticals to present FREEDOM-301 Phase 3 trial data for migraine at EHMTIC Congress

GSK and Amicus announce Amigal development and commercialization agreement

Shire announces results of Vyvanse Phase 2 signal finding study for Major Depressive Disorder

57% of ALK-positive advanced non-small cell lung cancer patients respond to crizotinib: Study

ImmuneRegen's Homspera enhances survival of animals vaccinated with experimental melanoma vaccine

Coadministration of INTUNIV tablets with stimulant reduces ADHD symptoms

Forest, Almirall report topline results from aclidinium bromide comparative Phase III study in COPD

StemCells initiates HuCNS-SC second clinical trial for Batten disease in children

Geron 2010 third quarter revenue increases from $494,000 to $546,000

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

Latest News